Updates are available Correction dated 2019-11-27
Click to view Correction: https://doi.org/10.1186/s12909-019-1873-7
-
Authors
Imam, Zaid https://orcid.org/0000-0002-3030-6188
Cappell, Mitchell S. https://orcid.org/0000-0003-3445-5428
- License Information
-
More Information
Article History
Received: 8 May 2019
Accepted: 15 October 2019
First Online: 4 November 2019
Change Date: 27 November 2019
Change Type: Correction
Change Details: Following publication of the original article [1], due to miscommunication during proofing, the author notified us the bellow corrections. In this Correction, correct and incorrect versions are shown.
Ethics approval and consent to participate
: The Institutional Review Board (IRB) granted IRB exemption/approval for this study on January 28, 2018 (IRB Number: 2017–382). IRB approval includes ethics approval and consent to participate. See attached IRB letter dated 12/8/17 by Graham Krasan, MD, Chairperson of Institutional Review Board.
: The Institutional Review Board (IRB) granted IRB exemption/approval for this study on January 28, 2018 (IRB Number: 2017–382). This includes consent for publication. See attached IRB letter dated 12/8/17 by Graham Krasan, MD, Chairperson of Institutional Review Board.
: None for either Dr. Imam or Dr. Cappell. In particular, Dr. Cappell, as a consultant for the United States Food and Drug Administration (FDA) Advisory Committee for Gastroenterology Drugs, affirms that this paper does not discuss any proprietary confidential pharmaceutical data submitted to the FDA and reviewed by Dr. Cappell. Dr. Cappell was until 1 year ago a member of the speaker’s bureau for AstraZeneca and Daiichi Sankyo, co-marketers of Movantik. Dr. Cappell has had one-time consultancies for Mallinckrodt and Shire more than 1 year ago. This work does not discuss any drug manufactured or marketed by AstraZeneca, Daiichi Sankyo, Shire, or Mallinckrodt.
